Introduction
The past decade has seen rapid development in the field of novel drugs and therapeutic biological agents. Despite the remarkable innovations that took place in the field of novel therapeutics, marketing authorization for promising novel therapies is time consuming, which can be at times distressing for some patients, particularly, those with severe diseases (1). This implies a serious bearing on the overall quality of life in such patients, because treatment can be challenging and at times inadequate with currently authorized medicines (1). Hence, new drugs that are unauthorized or in the late phase of clinical trials are the only hope for a plausible successful treatment in such patients.
In the past, clinical trials were the only way for patients in many countries to access drugs under development (2). However, clinical trials are timeconsuming and expensive, and not every patient meets enrolment criteria for specific clinical trials (1). Also, participation in clinical trials is a difficult choice for patients with life-threatening, long-lasting or seriously debilitating diseases. Nonetheless, in recent times, early access programs have opened doors to more possibilities for such patients, of which "Compassionate Use Program (CUP)" is one. There are approximately 7,000 different types of rare diseases (3) . Globally, it is estimated that approximately 350 million people suffer from rare diseases of which around 8.6% are from Europe (3) . Since 2010, the number of compassionate use requests has risen by nearly 25% and a major proportion of these requests are from rare disease patient populations, owing to highly engaged patients and caregivers connected to advocacy groups (4) . Many pharmaceutical companies are developing new therapies for patients with rare, life-threatening genetic diseases and are also facilitating access to such drugs (5) . Lately, Genzyme Corporation has donated imiglucerase to hundreds of severely affected patients with Gaucher's disease in three large-scale international CUP (6, 7) . Such efforts by pharma majors to improve early access to life-threatening disease drugs makes it essential to understand CUP and the processes involved.
CUP are early access programs intended to facilitate the availability of new medicines to patients suffering with life threatening disorders or diseases in the EU member states (Figure 1 ) (6) . In general, CUP are considered in the early stages of the product development cycle where patients get pre-launch access to the investigational drugs or drugs not yet authorized in the country. Unlike clinical trials, which are protocol driven and where participants have to meet certain inclusion and exclusion criteria, CUP allows patients without considering any criteria. But, CUP enrolls patients as per the laws and regulations outlined for the program (2). The European Medicines Agency (EMA) defines "compassionate use" as a treatment option that allows the use of an unauthorized medicinal product which is under development (8) .
T h e E M A p r o v i d e s r e c o m m e n d a t i o n s f o r compassionate use through the Committee for Medicinal Products for Human Use (CHMP). Also, laws and regulations are set by the EMA for compassionate use in the European Union (EU) ( Table 1) (8) (9) (10) (11) . Every EU member state has developed its own legislation for CUP based on the EMA recommendations and legal framework. Therefore, it is necessary for stakeholders such as, health professionals, patients and patient organizations, pharmaceutical companies and policy makers to be informed of legislation and processes that facilitate or gain access to innovative medicines at the earliest.
Despite the availability of previous reviews and studies on CUP and related processes in the EU member states, the available information is superficial and limited to selected countries in the EU (2,6,12). Besides, a few gaps exist in the literature, due to changes and revisions of regulations and pathways that happen over time (13) . Hence, there is a dearth of information in the published literature on existing CUP and current trends in all EU member states. Therefore, through this literature review we explored the presence of CUP in 28 EU member states to bridge the gaps for a better understanding of the legislation and specifics on CUP in every state.
The objectives of this review are to appraise the existing structure and processes for CUP in 28 EU member states, consolidate the information and present it as a comprehensive overview of the program in the countries. Article 6 of Directive 2001/83/EC1 of the EU requires that medicinal products be authorized before they are marketed in a community. Previously, a clinical trial was the only option for using unauthorized medicinal products. However, CUP created a treatment option for patients in the EU suffering from a disease without existing satisfactory authorized therapy alternatives or who could not be part of a clinical trial. The EMA recommends compassionate use through the Committee for Medicinal Products for Human Use (CHMP) and a legal framework. [16] [17] [18] [19] [20] . Moreover, these terms vary based on geographic location and are often used interchangeably. Also, they can imply different ideas with respect to the geographic area (18) . Nonetheless, all these programs make a drug available to a patient prior to authorization and commercial launch in the country (2,18).
Regulations for CUP
This literature review reports the most recent CUP related processes in the EU member states. The appraisal of available literature such as government websites and reports revealed a strong evidence of adoption of CUP. There was a significantly positive correlation between the EU and individual country laws and recommendations. The results from the reviewed literature on CUP are summarized in Table 2 to Table  7 . The tables compile the definition and an overview of CUP along with the medicinal products under it. On the whole, CUP was in place in 20 EU member states (71%) (Figure 2 ). These countries were Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Latvia, Malta, Netherlands, Portugal, Romania, Slovenia, Spain, Sweden and United Kingdom (UK). The remaining eight countries (Cyprus, Estonia, Greece, Ireland, Lithuania, Luxembourg, Poland and Slovakia)
Methodology
Data was collected through an extensive literature review process to present the consolidated information. First, search terms like "compassionate use," "expanded access," "patient access programs," "medicines/drugs regulations," and "access to new drugs" were defined and included for each member state. Data was extracted using the country-specific search terms from diverse fields of study such as: health policies, medicines for rare diseases, pricing and reimbursement, health care access, health services research, and Federal documents. Iterative database (PubMed MEDLINE) searches were conducted to retrieve articles related to CUP. Since the subject required a thorough and systematic search for literature on regulations and CUP details, the data sources were not limited to articles published in journals, but also included grey literature. The sources for grey literature included: i) Government websites of respective countries; ii) Institutional repositories like the EU Commission, EMA and Rare Diseases Europe (Eurordis); iii) The EUR-Lex for legal documents portraying the medical laws, acts and compassionate use; iv) Bielefeld Academic Search Engine (BASE); v) OpenGrey; vi) Google; and vii) Others (blogs, newsletters and forums).
Additionally, a reference list of relevant articles was reviewed to find other studies. Subsequently, after abstract sifting, relevant articles that described CUP, its regulations and other related information for each member state were retrieved for further study. In instances where the current CUP information in a member state could not be ascertained or was not retrievable through literature search, it was labeled as unavailable. Data were recorded based on a set of three key themes: i) The CUP and a brief overview of the program including its definition in 28 EU member states; ii) National regulations on CUP in each of the 28 EU member states; iii) National authorities responsible for CUP.
For the purpose of this review, the countries under study were stratified into six factions. The EU5 countries are the first faction as they are referred to the most. The rest of the five factions comprise countries classified based on United Nations Geoscheme namely: Western Europe, Eastern Europe, Northern Europe, Southern Europe and Asia. Specific insights from the literature are presented as tables and charts for a meaningful comparison of CUP legislation and processes among the EU member states.
Findings

Early access program
Most of the EU member states have special programs that facilitate early patient access to new medicines through a national authority (14, 15) . However, the Among the 28 EU member states, 18 (~64%) had nationalized regulations in place and the processes for CUP were well-defined as per the information gathered ( Figure 3 ). These countries are Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Romania, Slovenia, Spain, Sweden and United Kingdom. The decisions were managed and approvals were granted by a competent National Agency in the countries where CUP existed (12) .
According to this review, few countries lack official CUP and regulations. Every EU member state has nationalized regulations based on the EU framework. The national CUP makes medicinal products available either to individuals (NPP) or cohorts of patients governed by every member state's legislation. However, named patient basis is not CUP as per the EU regulations. So, the doctor responsible for the treatment contacts the manufacturer directly (9, (19) (20) (21) . CUP in 28 member states categorized by UN Geoscheme are summarized below.
CUP in EU5:
France has an elaborate scheme for CUP called Temporary Authorizations for Use (ATU). It allows the exceptional use of medicinal products without a marketing authorization and not subject to a clinical trial. The program is well-defined with structured regulations and procedures in the rest of EU5 namely (Table 5) (12, 31, (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) .
CUP Eastern European countries: Czech Republic, Bulgaria, Hungary and Romania have CUP with legislation in place. There is no CUP in Poland. In Slovakia, there is no CUP, but participation of patients in international registries influences CUP (Table 6 ) (12, 31, (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) .
CUP in Asia: There are no regulations allowing access to unauthorized medicinal products outside clinical trials in Cyprus (Table 7 ) (83).
Recent changes
The literature review deduces that countries like Hungary and Sweden, without national legislation previously, have now formulated them (13). Newly shaped policies and regulations have resulted due to higher demand for CUP, especially for orphan drugs for rare diseases. Clear regulations aid in systematizing CUP and providing better access to medicines. For instance, more than 20,000 patients were treated with over 200 products under French legislation for compassionate use by 2007 (84) . A study on all ATUs with marketing authorization between 01 January, 2005, and 30 June, 2010, concluded that the licensing and public bodies' review time was shortened by a combined total of 36 months. Also, the French ATU program accelerated the availability of new drugs in spite of the longer standard administrative path (85) . Since 2006, the EU member states submitted more than 50 CUP notifications to the EMA, of which around two-fifths were for orphan medicinal products (6).
Benefits of CUP
Implementing early access programs like CUP has multifold benefits, both to patients and pharmaceutical companies (18, (86) (87) (88) (89) (90) (91) (92) . First, CUPs benefit patients unable to participate in clinical trials due to mobility issues or who fail to fulfill the eligibility criteria (13). They are also preferred when no treatment options are available or access to investigational drug/biologics/ medical devices is the last resort for patients suffering from serious diseases/disorders (13) . Through early access programs, patients have access to promising drugs at an earlier stage during the life cycle, for instance, post phase II. Otherwise, patients have to wait for a considerable amount of time until the drug In Slovenia, in line with the EU regulation, CUP is: -The administration of a new active ingredient, constituting a significant therapeutic, scientific and technical innovation -For drugs obtaining marketing authorization or clinical testing of medicines -For a group of patients with a chronically or seriously debilitating disease that cannot be satisfactorily treated with medicines that have marketing authorization -The sponsor/manufacturer of a CUP must provide the product free of charge, which includes the costs of supply and wholesale distribution. is authorized and is on the market, if not for the early access programs (13) . Second, pharmaceutical and biotechnology companies provide a fast and efficient response to patient demand outside of traditional access routes due to such programs (87, 90) . Early access facilitates the smoother transition of a drug from clinical trials to the market and also prepares companies to develop global launch strategies based on global usage patterns and market landscape predictions (86, 88, 89) . Besides, the market authorization holders get the opportunity to resolve any product related issues and can overcome challenges encountered by preapproved drugs through early access (19, 88) . Above all, early access furnishes valuable information pertaining to real world evidence for practice and further research (18, 20) . Furthermore, patients, physicians and patient organizations are increasingly becoming aware of the possibilities to access a drug through such early access programs. Moreover, the existing framework for compassionate use in the EU member states can be effectively utilized to plan new access programs. For instance, the adaptive pathways approach, a scientific concept for medicine development and data generation, is part of the EMA's efforts to improve timely access for patients to new medicines that utilize the existing EU regulatory framework for medicines (93, 94) .
Challenges in implementing CUP
The governments and pharmaceutical companies are taking steps to implement CUP considering the benefits and importance of early access to drugs. However, it is highly challenging and complex for pharmaceutical companies to initiate early access programs like CUP. First, despite the existing EU Regulations, pharmaceutical companies face challenges as the regulations vary from country to country. This mandates regulators, policy makers and other key stakeholders to streamline processes and create transparency. Second, innovative drugs are relatively expensive and are becoming increasingly difficult for governments and payers to include them in their reimbursement schemes. This mandates for clearly set regulations and rationalized procedures to help patients, patient organizations and physicians for better access to drugs. Additionally, it is imperative for pharmaceutical companies to be updated on these regulations and processes on CUP for easier entrance into a market.
Strengths and limitations of this study
This review has its own strengths and limitations. Previously, the information available publicly on CUP, especially on legislation was limited and in many cases outdated when compared with the available grey literature (6, 12, 13) . However, the current systematic search addresses these gaps by including data from grey literature and peer-reviewed journal articles. Despite the efforts by researchers to capture all the available data, there still exist a few gaps in the literature. For instance, information on CUP is not available online for certain member states where CUP is still in the initial stages.
Conclusion and recommendations
Overall, this review identified the presence of CUP and highlighted its current status and legislation in 28 EU member states. This review found that CUP has a positive impact and potential benefits for patients and pharmaceutical companies. The established legislation for CUP in the EU member states suggests that the EU countries are ready to adopt methods for early access to medicines. An implication of this is the possibility to make new medicines available within a shorter time span for patients. Furthermore, the existing framework for compassionate use in the EU member states can pave the way for more access programs. Further research is necessary to determine the specific phases involved in the CUP, pricing and reimbursement frameworks in countries. Case studies and success stories which reflect the benefits of such early access programs from both patients' and other stakeholders' perspectives can give the relevant impetus for education on such programs. Since inadequate information on healthcare access can often be a stumbling block for stakeholders, periodic reviews need to be taken to throw light on emerging changes within the regulatory structures, both at European and member state levels to discern market trends. 
